Neurology / Alzheimer's Disease

Investigational Alzheimer's Drug Shows Effects in Inherited Early-Onset Disease
3 min read
fairly difficult
Gantenerumab improves amyloid, tau, neurodegeneration biomarkers
Gantenerumab significantly improved tau and other Alzheimer's disease biomarkers, but showed no evidence of cognitive benefit in a small study from the Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU).

The DIAN-TU-001 trial evaluated two investigational anti-amyloid antibodies, gantenerumab and solanezumab, in 144 people with a rare, early-onset form of Alzheimer's known as dominantly inherited Alzheimer's disease (DIAD). Individuals with DIAD develop Alzheimer's dementia at a predictable age and show pathological signs of disease years before symptom onset.

In people with DIAD, gantenerumab significantly reduced amyloid plaques and lowered cerebrospinal fluid (CSF) total tau and phosphorylated-tau181 (p-tau181) levels compared with placebo, reported Randall Bateman, MD, of Washington University School of Medicine in St. Louis, and co-authors in Nature Medicine. It also curbed increases in neurofilament light chain (NfL), a marker of neurodegeneration.

"The drug's ability to shift multiple Alzheimer's biomarkers toward normal indicates that it is positively affecting the disease process," Bateman said in a statement.

"Although the trial focuses on people with rare mutations, drugs that are successful in this population would be promising candidates for preventing or treating the forms of Alzheimer's that occur more commonly in older adults," he added. "The destructive molecular and cellular processes in the brain are similar in both types of the…
Judy George
Read full article